U.S. flag

An official website of the United States government

GTR Home > Conditions/Phenotypes > Migraine, familial hemiplegic, 1

Migraine, familial hemiplegic, 1

Synonyms
MIGRAINE, FAMILIAL HEMIPLEGIC 1, WITH PROGRESSIVE CEREBELLAR ATAXIA

Summary

Familial hemiplegic migraine (FHM) falls within the category of migraine with aura. In migraine with aura (including FHM) the neurologic symptoms of aura are unequivocally localizable to the cerebral cortex or brain stem and include visual disturbance (most common), sensory loss (e.g., numbness or paresthesias of the face or an extremity), and dysphasia (difficulty with speech). FHM must include motor involvement, such as hemiparesis (weakness of an extremity). Hemiparesis occurs with at least one other symptom during FHM aura. Neurologic deficits with FHM attacks can be prolonged for hours to days and may outlast the associated migrainous headache. FHM is often earlier in onset than typical migraine, frequently beginning in the first or second decade; the frequency of attacks tends to decrease with age. Approximately 40%-50% of families with CACNA1A-FHM have cerebellar signs ranging from nystagmus to progressive, usually late-onset mild ataxia. [from GeneReviews]

Available tests

65 tests are in the database for this condition.

Check Related conditions for additional relevant tests.

Clinical tests (65 available)

Molecular Genetics Tests

Genes See tests for all associated and related genes

  • Also known as: APCA, BI, CACNL1A4, CAV2.1, DEE42, EA2, EIEE42, FHM, HPCA, MHP, MHP1, SCA6, CACNA1A
    Summary: calcium voltage-gated channel subunit alpha1 A

Clinical features

Help
Imported from Human Phenotype Ontology (HPO)

Show allHide all

Reviews

Clinical resources

Practice guidelines

  • NICE, 2021
    UK NICE Guideline CG150, Headaches in over 12s: diagnosis and management, 2021
  • Orphanet, 2013
    Orphanet, Hemiplegic Migraine (HM), 2013

Molecular resources

Consumer resources

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.